Abstract: Novel 4,5-dihydro-4,4-dialkyl-6-(substituted)phenyl-3(2H)-pyridazinones having unexpected activity for use as cardiotonic and antihypertensive agents.

Abstract: Substituted 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinone compounds and 6-(substituted)phenyl-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents.Said compounds cause a significant increase in myocardial contractility in the dog. Said compounds also cause a decrease in blood pressure in the spontaneously hypertensive rat. Said compounds are produced by reacting substituted .gamma.-oxobenzenebutanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones which are dehydrogenated to 6-(substituted)phenyl-3(2H)-pyridazinones.Both the intermediate 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones and the 6-(substituted)phenyl-3(2H)-pyridazinones are useful as cardiotonic and antihypertensive agents.

Abstract: A novel method of producing 4,5-dihydro-6-(substituted)phenyl-5-methyl-3(2H)-pyridazinone compounds and the corresponding pharmaceutically acceptable salt compounds is provided as well as pharmaceutical compositions containing one or more of the compounds as active components of the compositions for their pharmacological activity, particularly their cardiotonic and/or antihypertensive activity.Said 5-methylpyridazinone compounds have greatly improved cardiotonic activity in vivo that causes, for example, a significant increase in myocardial contractility in the dog. Said compounds also cause a decrease in blood pressure in the spontaneously hypertensive rat. Said compounds are produced by a stepwise procedure in which one reacts a substituted morpholineacetonitrile with crotononitrile to obtain the corresponding 4-(substituted)-.beta.-methyl.gamma.-oxobenzenebutanoic acid and reacts the latter acid with hydrazine to provide the 4,5-dihydro-6-(substituted)phenyl-5-methyl-3(2 ,uns/H/ )-pyridazinone product.

Abstract: Substituted 2,5-dihydro- and 2,4,4a,5-tetrahydro-3H-indeno[1,2-c]pyridazin-3-ones and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents.

Abstract: N.sup.6 -Tricyclic adenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical composition and methods for using said compounds and compositions are described.

Abstract: N.sup.6 -Substituted diarylalkyladenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are described.

Abstract: N.sup.6 -Substituted diarylalkyladenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are described.

Abstract: (S)-N.sup.6 -2-Hydroxypropyladenosines and pharmaceutically acceptable acid addition salts having highly desirable antihypertensive properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are described.

Abstract: Certain 2(1H)-pyridinones are cardiotonic agents. Methods for their preparation and use are disclosed.

Abstract: Substituted 2,5-dihydro- and 2,4,4a,5-tetrahydro-3H-indeno[1,2-c]pyridazin-3-ones and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents.

Abstract: N.sup.6 -Tricyclic adenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are described.

Abstract: 4,5-Dihydro-6-[(substituted)-1H-imidazol-4-yl or 5-yl]-3(2H)-pyridazinones 6-[(substituted)-1H- imidazol-4-yl or 5-yl]-3(2H)-pyridazinones and pharmaceutically acceptable acid addition salts thereof are useful as cardiotonic and antihypertensive agents.The above compounds cause a significant increase in myocardial contractility in the dog and also cause a decrease in blood pressure in the spontaneously hypertensive rat. The compounds are produced by reacting the appropriate .gamma.-oxo-imidazolebutanoic acid with a suitably substituted hydrazine to provide 4,5-dihydro-6-(substituted)imidazolyl-3(2H)-pyridazinones which are oxidized to 6-(substituted)imidazolyl-3(2H)-pyridazinones.

Abstract: There are disclosed herein certain substituted imidazo[1,2-a]pyrazine compounds which are useful in the treatment of peptic ulcer diseases.

Abstract: Certain 2(1H)-pyridinones are cardiotonic agents. Methods for their preparation and use are disclosed.

Abstract: There are disclosed herein certain substituted imidazo[1,2-b]pyridazine compounds which are useful in the treatment of peptic ulcer diseases.

Abstract: Substituted 8-phenylxanthines and their use as bronchodilators is described. Methods for their preparation and use as well as pharmaceutical compositions containing them are also described.

Abstract: This invention relates to imidazo[1,2-a]pyridine derivatives which are useful in the treatment of peptic ulcer diseases.

Abstract: There are disclosed herein certain indole derivatives which are useful in the treatment of peptic ulcer diseases.

Abstract: The invention relates to imidazo[1,5-a]pyridine derivatives which are useful in the treatment of peptic ulcer diseases.

Abstract: Disclosed herein are certain imidazo[1,5-a]pyridines, and pharmaceutical compositions containing them as the active ingredient for treatment and promotion of healing of peptic ulcer disease by virtue of their antisecretory and cytoprotective properties.